Consequences of renal insufficiency on the hepatic clearance of some drugs.
There have been numerous investigations into the effect of kidney or liver diseases on the renal or hepatic elimination of drugs, but little is known about the possible consequences of renal insufficiency on the hepatic clearance of medicinal agents. The first reports of diminished presystemic elimination of drugs in renal failure were presented by Bianchetti in 1976 for propranolol and by Levy in 1979 for dextropropoxyphene. We confirmed the fact that the hepatic presystemic elimination of drugs might be diminished by kidney diseases. We studied this phenomenon with the beta-blocking agents tolamolol, bufuralol and oxprenolol. Tolamolol is eliminated from the body mainly by aromatic hydroxylation and, for bufuralol, aliphatic hydroxylation also plays an important role, whereas, for oxprenolol, glucuroconjugation of the unchanged compound is an important route of elimination. After oral administration, the areas under the plasma/blood concentration curves were markedly increased in patients with renal insufficiency as compared to healthy subjects. The clearance approach of Rowland and Tozer led to the conclusion that decrease of the presystemic hepatic elimination might be the main reason for this finding. Cefoperazone is a cephalosporin eliminated to 75% by the biliary route under normal conditions. In a study in which the drug was intravenously infused to both healthy volunteers and patients with renal insufficiency, we found that in some patients the extrarenal clearance was markedly reduced. It is probable that in this situation the patients also suffered from a slight hepatic insufficiency, as sometimes observed in the case of kidney disease associated with a poor physical condition. It is well-known that in patients with terminal liver failure, the kidney may also be involved, producing a condition known as the "hepato-renal" syndrome. We feel that there is evidence to support the hypothesis that renal failure can disturb the pharmacokinetics of drugs by processes other than merely reducing their renal excretion. The precise causes of the decreased hepatic elimination found in renal patients remains, however, to be determined.
D000319:Adrenergic beta-Antagonists / Q000378:metabolism*; D001711:Biotransformation; D011431:Dextropropoxyphene / Q000378:metabolism; D004983:Ethanolamines / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008954:Models, Biological; D010096:Oxprenolol / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism* / Q000652:urine; D011412:Propanolamines / Q000378:metabolism; D011433:Propranolol / Q000378:metabolism; D006435:Renal Dialysis
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D004364:Pharmaceutical Preparations; D011412:Propanolamines; D010096:Oxprenolol; C010831:bufuralol; D011433:Propranolol; C100227:tolamolol; D011431:Dextropropoxyphene